recommended dosage for bpc 157 and tb500 KLOW Dosing Guide: GHK-Cu + KPV + BPC-157 + TB-500 Protocol & Reconstitution (2026) AOD-9604 - 5 antioxidative glutathione Size:500 Capsules
AOD-9604 - 5
Key selective action features: No Growth Hormone Receptor Binding: Does not activate GH receptors responsible for IGF-1 stimulation and systemic growth effects Preserved Glucose Metabolism: No impact on blood sugar regulation, insulin sensitivity, or diabetic risk markers No Tissue Growth Effects: Does not promote muscle hypertrophy, organ growth, or cell proliferation pathways Adipose-Specific Targeting: Works primarily through beta-3 adrenergic receptors concentrated in fat tissue No IGF-1 Elevation: Clinical trials confirmed no changes in serum IGF-1 levels at therapeutic doses Isolated Lipolytic Action: Maintains the fat-breaking properties of growth hormone fragment 176-191 without broader effects Selective Mechanism: Structural differences from full-length GH prevent binding to receptors mediating non-fat-related effects Clinical Validation: Human studies in 900+ participants confirmed selective fat metabolism without systemic hormonal changes The following guide provides detailed analysis of AOD-9604 ‘s selective action and why this selectivity matters for safe, targeted fat metabolism
antioxidative glutathione
Size:500 Capsules
This group includes compounds such as BPC-157, CJC-1295, ipamorelin, GHK-Cu, MOTS-c, semax, selank, and TB-500, several of which have been flagged by regulators or discussed in the literature as areas of uncertain safety, limited evidence, or nonapproved use [21,31,32]
